| Summary: | Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing’s disease and acromegaly. The liquid-phase total synthesis of pasireotide-a 18-membered cyclic hexapeptide-was achieved by the 3 + 2 + 1 strategy, and the Pro<sup>1</sup>-Phe<sup>6</sup> peptide bond was selected as the final cyclization position. Two key fragments were simply synthesized using <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide/<i>N</i>-hydroxysuccinimide ester (BSA/NHS) as coupling agents, and processes of the two key fragments were simple without any chromatographic purification. The current synthesis method is easily scalable and produces the target peptide with an overall yield of 15%.
|
|---|